Versant Ventures
A San Francisco life sciences venture firm that builds biotech companies in its own laboratories in North America and Europe. It created the radiopharmaceutical company RayzeBio and backed Gritstone, Repare and Abdera.
Overview
Versant Ventures has been 'delivering strong results since 1999' according to its homepage, which also states '$5.5B under management', six locations and three Discovery Engines: in-house teams of scientists in laboratory facilities that launch companies with academic founders. Wikipedia gives a 1999 founding and a San Francisco headquarters. The firm leads Series A rounds in its own creations and invests across Europe (Basel), Canada and the United States. Oncology is prominent in its news feed: RayzeBio (targeted radiopharmaceuticals, Series A, B and C releases 2020 to 2021), Abdera Therapeutics (antibody-based radiopharmaceuticals, 2023 debut), Vividion (precision oncology and immunology), Gritstone Oncology and Repare Therapeutics (synthetic lethality) all appear as Versant portfolio announcements.
Portfolio in OnCo (4)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Abdera Therapeutics Vancouver, CA | Startup | radiopharma | Small-cell lung cancer | Series B 2023, $110M |
| Firefly Bio South San Francisco, CA, US | Acquired | biotech | Acquisition 2026, $1B | |
| Nested Therapeutics Cambridge, MA, US | Startup | biotech | Series A 2022, $90M | |
| Stablix New York, NY, US | Startup | biotech | Series A 2021, $63M |
Notes
top- The portfolio page is rendered client-side; examples come from press releases listed on the firm's news page.
Pages like this
not linked directly; found by shared links- CompanyCormorant Asset Management
Shares Stablix and the tag vc.
- CompanyMPM BioImpact
Shares Firefly Bio and the tag vc.
- CompanySection 32 (S32)
Shares Nested Therapeutics and the tag vc.
- CompanyForesite Capital
Shares Nested Therapeutics and the tag vc.